Agenda
Agenda correct at time of going to press
|
26 October 2011 |
||
|
19.00 |
Drinks for early arrivals and early registration |
|
|
27 October 2011 |
||
|
08.00 Registration Opens |
||
|
10.00 |
Welcome |
|
|
10.15 Session: Investment in CE Life Science Chair: Marcin Szumowski |
||
|
10.15 |
Talk: A perspective on life science and life science investment in CE Roland Kozlowski |
|
|
10.45 |
Talk: What’s best suited to the CE investor: devices, services, diagnostics or pharmaceuticals Michał Kostka; South Moravian Innovation Centre (Czech Republic) |
|
|
11.15 |
General Comments on the global picture and potential of CE and New Perspectives on EU grant funding for life sciences Oliver Murphy and Michał Turczyk; Deloitte (Poland) |
|
|
11.15 Coffee |
||
|
12.15 |
Panel Discussion: General and CE specific challenges facing investors in life sciences
Moderator: Roland Kozlowski
Robert Rzemiński; MCI (Poland)
Martin Oxley, UKTI (UK/Poland)
Martin Fusek; IOCB TTO (Czech Republic)
Marcell Veidner; Hungarian Biotech Association (Hungary) |
|
|
13.00 Lunch |
||
14.10 Session: Attracting investment and clients from beyond CE Chair: Martin Oxley (UKTI) |
||
|
14.10 |
Talk: Pharmaceutical venture funds what is the general expectation what are the thoughts on Central Europe Graeme Martin; Takeda Research Investment (US) |
|
|
14.40 |
Talk: What were your considerations for developing a business in the CE region Quintiles; Wojciech Przybyś (Poland) |
|
|
15.10 |
Panel Discussion: Attracting venture financing from abroad, what will investors look for?
Moderator: Martin Oxley
Quintiles; Wojciech Przybyś (Poland)
Sander van Deventer, Forbion (Netherlands)
Simon Kerr, Imperial Innovations (UK)
Jonathan Hepple, Seroba-Kernel (UK/Ireland) |
|
|
16.00 Tea |
||
|
16.30 |
ession: Private & young company presentations
Chair: Marcin Szumowski
BTM Sp. z o. o. (Marcin Szumowski; Poland)
Proteon Sp. z o. o. (Jarosław Dastych; Poland)
Hependo Sp. z o. o. (Łukasz Kutrzeba; Poland)
Biovectis (Krzystof Kucharczyk; Poland)
BBS Nanotechnology (Janos Borbely; Hungary)
Flavopharma Sp. z o. o. (Mikołaj Gurdała; Poland) |
|
|
18.00 |
Close for Day |
|
|
19.00 |
Conference Dinner and networking drinks |
|
|
28 October 2011 |
||
|
09.00 Session: Public Markets in Central Europe Chair: Oliver Murphy |
||
|
09.00 |
Talk: New Connect: its mission Emil Stępień; Polish Stock Exchange (Poland) |
|
|
09.30 |
Talk: Case studies from a New Connect Nominated Advisor Artur Chabowski; Acadia (Poland) |
|
|
10.00 |
Panel Discussion: Challenges for public market investment in CE Life Sciences Moderator: Oliver Murphy Artur Chabowski; Acadia (Poland) Emil Stępień; Polish Stock Exchange (Poland) Simon Wallwork, Semple Fraser LLP (UK) Emma Palmer Foster, EJ Palmer Consulting (UK) Piotr Czapski; EQT Partners (Poland) |
|
|
10.45 Coffee |
||
|
11.15 |
Recent life science listings on Poland’s alternative investment market: New Connect Selvita (Poland); Paweł Przewięźlikowski CEO Medicalgorithmics (Poland); Marek Dziubiński CEO |
|
|
11.45 |
Business in Krakow Paweł Węgrzyn; “Local Government Entrepreneurship Advisor” |
|
|
12.00 |
Panel Discussion: The way forward for the CE sector: lessons learnt from more mature markets Moderator: Roland Kozlowski Tadeusz Pietrucha; Biotech Consulting (Poland) Peter Neubeck; TVM (Germany) Piotr Lassota; Polpharma (Poland) Grazianno Seghezzi; Sofinnova (France) Paweł Błachno; JCI (Poland) |
|
|
12.45 |
Statement on Life Science in Poland Leszek Grabarczyk ; The National Centre for Research & Development |
|
|
13.00 |
Summing up Roland Kozlowski; (LSBC) & Oliver Murphy (Deloitte) |
|
|
13.15 Conference Close |
||